Genetic counseling and genetic testing for mutations in certain genes—e.g., BRCA1 and BRCA2—can help people understand their risk of certain types of cancer that can run in families, and improve outcomes through prevention, early detection, and targeted treatments, a study conducted at Rutgers Cancer Institutes found.
Scientists at VCU Massey Cancer Center discovered a previously unrecognized relationship between two sets of proteins that operate in tandem to fend off the growth of pancreatic cancer. The findings could provide information for the development of novel therapies for what is currently an incurable disease.
Lucem Health established an early disease detection solution, Lucem Health Reveal, which leverages existing EHR data to identify patients who may be at a higher risk of serious or chronic disease.
Leal Health, formerly known as Trialjectory, presented data on the negative impact of Eastern Cooperative Oncology Group, or ECOG, performance status scores on cancer patients’ eligibility to enroll in clinical trials at the American Society of Clinical Oncology Genitourinary Cancers Symposium.
The phase III SIERRA trial of iomab-B in patients age 55 and above with active relapsed or refractory acute myeloid leukemia, led by Actinium Pharmaceuticals Inc., showed positive results in its primary and secondary endpoints.
Results from the pivotal phase III KEYNOTE-859 trial showed that Keytruda (pembrolizumab) plus chemotherapy significantly improved overall survival for patients with human epidermal growth factor receptor 2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression.
Takeda Oncology presented efficacy and safety data from the phase III PhALLCON trial studying Iclusig (ponatinib) in adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia during a virtual American Society of Clinical Oncology’s Plenary Series Program Feb. 15.
The updated National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Breast Cancer Version 1.2023 recognize Agendia Inc.’s MammaPrint UltraLow Risk result and its proven impact on patient care.
In a phase II, single-arm study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, patients with resectable non-small cell lung cancer who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.
Three-year (36.5 months minimum; 44.0 months median) follow-up results from the phase III CheckMate -9ER trial demonstrated sustained survival and response rate benefits with the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma, according to Bristol Myers Squibb and Exelixis Inc.
